Outcomes by Transarterial Chemoembolization (TACE) Modality from Participants (pts) with Embolization-Eligible Hepatocellular Carcinoma (HCC) Treated with Durvalumab (D) + Bevacizumab (B) + TACE and Placebos (PBO) + TACE: EMERALD-1 Subgroup Analysis.

Jeong Heo,Takuji Okusaka,Jung-Hwan Yoon,Bruno Sangro,Stephen Lam Chan,Joseph P. Erinjeri, Marco Matos,Thomas Decaens,Eric Xueyu Chen, Muhammad S. Beg, Ana Maria Matilla, Le Thi Tuyet Phuong, Rebecca Griffin, Stephanie I. Udoye, Sandra Indiviglio,Masatoshi Kudo

Journal of Clinical Oncology（2025）

Cited 0|Views0

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined